O	0	12	Facilitating
O	13	21	decision
O	21	22	-
O	22	28	making
O	29	31	in
B-eligibility	32	37	women
I-eligibility	38	48	undergoing
I-eligibility	49	56	genetic
I-eligibility	57	64	testing
I-eligibility	65	68	for
I-eligibility	69	79	hereditary
I-eligibility	80	86	breast
I-eligibility	87	93	cancer
O	93	94	:
O	95	103	BRECONDA
O	104	114	randomized
O	115	125	controlled
O	126	131	trial
O	132	139	results
O	139	140	.

O	141	149	Decision
O	149	150	-
O	150	156	making
O	157	167	concerning
O	168	172	risk
O	172	173	-
O	173	181	reducing
O	182	192	mastectomy
O	193	196	for
O	197	202	women
O	203	205	at
O	206	216	hereditary
O	217	221	risk
O	222	224	of
O	225	231	breast
O	232	238	cancer
O	239	246	entails
O	247	254	complex
O	255	263	personal
O	264	271	choices
O	271	272	.

O	273	281	Deciding
O	282	289	whether
O	290	293	and
O	294	297	how
O	298	300	to
O	301	308	restore
O	309	315	breast
O	316	321	shape
O	322	327	after
O	328	332	risk
O	332	333	-
O	333	341	reducing
O	342	352	mastectomy
O	353	355	is
O	356	357	a
O	358	361	key
O	362	366	part
O	367	369	of
O	370	374	this
O	375	382	process
O	382	383	.

O	384	386	We
O	387	396	developed
O	397	398	a
B-intervention	399	402	web
I-intervention	402	403	-
I-intervention	403	408	based
I-intervention	409	417	decision
I-intervention	418	421	aid
O	421	422	,
O	423	431	BRECONDA
O	432	433	(
O	433	439	Breast
O	440	454	Reconstruction
O	455	463	Decision
O	464	467	Aid
O	467	468	)
O	468	469	,
O	470	472	to
O	473	479	assist
O	480	485	women
O	486	488	in
O	489	497	decision
O	497	498	-
O	498	504	making
O	505	514	regarding
O	515	521	breast
O	522	536	reconstruction
O	536	537	.

O	538	542	This
O	543	548	study
O	549	557	assessed
O	558	561	the
O	562	570	efficacy
O	571	573	of
O	574	582	BRECONDA
O	583	585	to
O	586	592	assist
O	593	598	women
O	599	601	at
O	602	611	increased
O	612	616	risk
O	617	619	of
O	620	626	breast
O	627	633	cancer
O	634	636	in
O	637	643	making
O	644	653	decisions
O	654	663	regarding
O	664	668	risk
O	668	669	-
O	669	677	reducing
O	678	688	mastectomy
O	689	691	in
O	692	697	terms
O	698	700	of
O	701	711	decisional
O	712	720	conflict
O	720	721	,
O	722	731	knowledge
O	731	732	,
O	733	736	and
O	737	749	satisfaction
O	750	754	with
O	755	766	information
O	766	767	.

B-eligibility	768	773	Women
I-eligibility	774	776	at
I-eligibility	777	787	hereditary
I-eligibility	788	792	risk
I-eligibility	793	795	of
I-eligibility	796	802	breast
I-eligibility	803	809	cancer
O	810	811	(
O	811	812	N
O	813	814	=
B-total-participants	815	817	64
O	817	818	)
O	819	823	were
O	824	833	recruited
O	834	838	into
O	839	843	this
O	844	854	randomized
O	855	865	controlled
O	866	871	trial
O	872	876	from
O	877	881	four
B-location	882	892	Australian
O	893	903	hereditary
O	904	910	cancer
O	911	918	clinics
O	918	919	.

O	920	932	Participants
O	933	942	initially
O	943	951	provided
O	952	958	online
O	959	966	consent
O	967	970	and
O	971	980	completed
O	981	989	baseline
O	990	1004	questionnaires
O	1005	1014	assessing
O	1015	1025	decisional
O	1026	1034	conflict
O	1034	1035	,
O	1036	1045	knowledge
O	1045	1046	,
O	1047	1050	and
O	1051	1063	satisfaction
O	1064	1068	with
O	1069	1080	information
O	1080	1081	.

O	1082	1086	They
O	1087	1091	were
O	1092	1096	then
O	1097	1105	randomly
O	1106	1114	assigned
O	1115	1117	to
O	1118	1124	either
O	1124	1125	:
O	1126	1127	1
O	1127	1128	)
O	1129	1141	Intervention
O	1142	1143	-
O	1144	1153	unlimited
O	1154	1160	access
O	1161	1163	to
O	1164	1172	BRECONDA
O	1172	1173	,
O	1174	1178	with
O	1179	1184	usual
O	1185	1189	care
O	1189	1190	;
O	1191	1193	or
O	1193	1194	,
O	1195	1196	2
O	1196	1197	)
B-control	1198	1205	Control
I-control	1206	1207	-
I-control	1208	1213	usual
I-control	1214	1218	care
O	1218	1219	.

O	1220	1222	At
O	1223	1224	2
O	1224	1225	-
O	1225	1231	months
O	1232	1238	follow
O	1238	1239	-
O	1239	1241	up
O	1242	1243	(
O	1243	1244	N
O	1245	1246	=
B-total-participants	1247	1249	60
O	1249	1250	)
O	1251	1254	the
O	1255	1263	outcomes
O	1264	1268	were
O	1269	1271	re
O	1271	1272	-
O	1272	1280	assessed
O	1280	1281	.

O	1282	1294	Intervention
O	1295	1307	participants
O	1308	1312	also
O	1313	1322	completed
O	1323	1327	user
O	1328	1341	acceptability
O	1342	1349	ratings
O	1350	1353	for
O	1354	1357	the
O	1358	1370	intervention
O	1371	1378	overall
O	1379	1382	and
O	1383	1391	specific
O	1392	1395	key
O	1396	1403	modules
O	1403	1404	.

O	1405	1412	MANCOVA
O	1413	1421	analyses
O	1422	1431	indicated
O	1432	1436	that
O	1437	1449	Intervention
O	1450	1462	participants
O	1463	1471	reported
B-outcome	1472	1477	lower
I-outcome	1478	1488	decisional
I-outcome	1489	1497	conflict
O	1498	1499	(
O	1499	1500	P
O	1501	1502	=
O	1503	1504	0
O	1504	1505	.
O	1505	1508	027
O	1508	1509	)
O	1509	1510	,
O	1511	1514	and
B-outcome	1515	1522	greater
I-outcome	1523	1532	knowledge
O	1533	1534	(
O	1534	1535	P
O	1536	1537	=
O	1538	1539	0
O	1539	1540	.
O	1540	1543	019
O	1543	1544	)
O	1545	1548	and
B-outcome	1549	1561	satisfaction
I-outcome	1562	1566	with
I-outcome	1567	1578	information
O	1579	1580	(
O	1580	1581	P
O	1582	1583	<
O	1584	1585	0
O	1585	1586	.
O	1586	1590	0005
O	1590	1591	)
O	1592	1594	at
O	1595	1596	2
O	1596	1597	-
O	1597	1603	months
O	1604	1610	follow
O	1610	1611	-
O	1611	1613	up
O	1614	1622	compared
O	1623	1627	with
O	1628	1636	Controls
O	1636	1637	.

O	1638	1650	Intervention
O	1651	1663	participants
O	1664	1672	reported
O	1673	1677	high
B-outcome	1678	1682	user
I-outcome	1683	1696	acceptability
I-outcome	1697	1700	and
I-outcome	1701	1713	satisfaction
O	1714	1718	with
O	1719	1722	the
O	1723	1735	intervention
O	1735	1736	.

O	1737	1745	BRECONDA
O	1746	1754	benefits
O	1755	1760	women
O	1761	1772	considering
O	1773	1777	risk
O	1777	1778	-
O	1778	1786	reducing
O	1787	1797	mastectomy
O	1798	1800	by
O	1801	1809	reducing
O	1810	1820	decisional
O	1821	1829	conflict
O	1829	1830	,
O	1831	1834	and
O	1835	1844	improving
O	1845	1854	knowledge
O	1855	1858	and
O	1859	1871	satisfaction
O	1872	1876	with
O	1877	1888	information
O	1888	1889	.

O	1890	1895	These
O	1896	1904	benefits
O	1904	1905	,
O	1906	1913	coupled
O	1914	1918	with
O	1919	1923	high
O	1924	1928	user
O	1929	1942	acceptability
O	1942	1943	,
O	1944	1955	demonstrate
O	1956	1959	the
O	1960	1971	feasibility
O	1972	1974	of
O	1975	1987	implementing
O	1988	1996	BRECONDA
O	1997	1999	in
O	2000	2003	the
O	2004	2014	hereditary
O	2015	2021	cancer
O	2022	2026	risk
O	2027	2034	context
O	2034	2035	.
